Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers
JA Westwood, GM Matthews, J Shortt, D Faulkner… - Leukemia research, 2014 - Elsevier
In order to stimulate antigen presentation and T cell activity against cancer, we treated three
different tumor models in mice with the monoclonal antibodies anti-CD40 plus anti-CD137
(BiMab). In a subcutaneous transplantable MC38 colon cancer model, there was significant
enhancement in the survival of mice following BiMab treatment. Anti-CD40 has shown
considerable success against lymphoma in previous studies by other investigators, and we
also showed in this study that, in a model of Eμ-Myc lymphoma, there was a statistically …
different tumor models in mice with the monoclonal antibodies anti-CD40 plus anti-CD137
(BiMab). In a subcutaneous transplantable MC38 colon cancer model, there was significant
enhancement in the survival of mice following BiMab treatment. Anti-CD40 has shown
considerable success against lymphoma in previous studies by other investigators, and we
also showed in this study that, in a model of Eμ-Myc lymphoma, there was a statistically …